PMID- 16858070
OWN - NLM
STAT- MEDLINE
DCOM- 20060928
LR  - 20190722
IS  - 0009-9147 (Print)
IS  - 0009-9147 (Linking)
VI  - 52
IP  - 9
DP  - 2006 Sep
TI  - Lack of comparability of intact parathyroid hormone measurements among commercial 
      assays for end-stage renal disease patients: implication for treatment decisions.
PG  - 1771-6
AB  - BACKGROUND: Variability among assays used to measure intact parathyroid hormone 
      (iPTH) is of particular concern because of the routine use of iPTH assay results 
      to guide management of osteodystrophy and calcium metabolism in patients with 
      end-stage renal disease (ESRD). The aim of this study was to determine the extent 
      to which results from commercially available iPTH assays diverge from results 
      obtained with the Nichols Allegro(R) Intact PTH immunoradiometric assay (IRMA), 
      which was used as evidence in the development of the National Kidney Foundation's 
      Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines. METHODS: 
      We divided EDTA plasma from 46 dialysis patients with ESRD and measured iPTH 
      values with the following commercially available iPTH assays: Nichols' Allegro 
      iPTH IRMA, Nichols Advantage iPTH immunochemiluminescent assay (ICMA), 
      Scantibodies' Total Intact PTH IRMA, DiaSorin's N-tact iPTH IRMA, DPC's 
      Coat-A-Count iPTH IRMA, Roche's Elecsys iPTH ICMA, and DSL's Active iPTH IRMA. 
      RESULTS: Method comparison showed considerable interassay differences in the 
      measurement of iPTH in ESRD patients. IPTH values assessed by other methods 
      ranged, on average, from 60% to 152% of the Nichols Allegro IRMA values. Of the 6 
      iPTH assays tested, only the Scantibodies Total Intact PT IRMA (P = 0.7554) and 
      the Roche Elecsys iPTH ICMA (P = 0.1327) resulted in iPTH values not 
      statistically different from those obtained with the Nichols Allegro iPTH IRMA. 
      CONCLUSIONS: Noncomparability among iPTH assays remains a distinct problem for 
      the management of ESRD patients. These results should be taken into consideration 
      when determining the course of medical treatment based on measured iPTH 
      concentrations.
FAU - Cantor, Tom
AU  - Cantor T
AD  - Scantibodies Laboratory, Inc., Santee, CA 92071, USA. tom.cantor@scantibodies.com
FAU - Yang, Zan
AU  - Yang Z
FAU - Caraiani, Nicolae
AU  - Caraiani N
FAU - Ilamathi, Ekambaram
AU  - Ilamathi E
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20060720
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Parathyroid Hormone)
SB  - IM
CIN - Clin Chem. 2010 Mar;56(3):489-90. PMID: 20190152
MH  - Chronic Kidney Disease-Mineral and Bone Disorder/diagnosis/etiology
MH  - Humans
MH  - Immunoassay/methods
MH  - Kidney Failure, Chronic/complications/*diagnosis/therapy
MH  - Parathyroid Hormone/*blood
MH  - Renal Dialysis
EDAT- 2006/07/22 09:00
MHDA- 2006/09/29 09:00
CRDT- 2006/07/22 09:00
PHST- 2006/07/22 09:00 [pubmed]
PHST- 2006/09/29 09:00 [medline]
PHST- 2006/07/22 09:00 [entrez]
AID - clinchem.2006.071589 [pii]
AID - 10.1373/clinchem.2006.071589 [doi]
PST - ppublish
SO  - Clin Chem. 2006 Sep;52(9):1771-6. doi: 10.1373/clinchem.2006.071589. Epub 2006 
      Jul 20.